CY1115841T1 - Εμβολια πεπτιδιου παραγομενα απο epha4 - Google Patents
Εμβολια πεπτιδιου παραγομενα απο epha4Info
- Publication number
- CY1115841T1 CY1115841T1 CY20141101067T CY141101067T CY1115841T1 CY 1115841 T1 CY1115841 T1 CY 1115841T1 CY 20141101067 T CY20141101067 T CY 20141101067T CY 141101067 T CY141101067 T CY 141101067T CY 1115841 T1 CY1115841 T1 CY 1115841T1
- Authority
- CY
- Cyprus
- Prior art keywords
- peptides
- present
- epea4
- shape
- seq
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 206010001497 Agitation Diseases 0.000 abstract 1
- 102100024153 Cadherin-15 Human genes 0.000 abstract 1
- 102100036109 Dual specificity protein kinase TTK Human genes 0.000 abstract 1
- 101150078651 Epha4 gene Proteins 0.000 abstract 1
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 abstract 1
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 abstract 1
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 abstract 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 abstract 1
- 101000839066 Homo sapiens Hypoxia-inducible lipid droplet-associated protein Proteins 0.000 abstract 1
- 101001054725 Homo sapiens Inhibin beta B chain Proteins 0.000 abstract 1
- 101001027621 Homo sapiens Kinesin-like protein KIF20A Proteins 0.000 abstract 1
- 101001112162 Homo sapiens Kinetochore protein NDC80 homolog Proteins 0.000 abstract 1
- 101000817237 Homo sapiens Protein ECT2 Proteins 0.000 abstract 1
- 102100028891 Hypoxia-inducible lipid droplet-associated protein Human genes 0.000 abstract 1
- 102100027003 Inhibin beta B chain Human genes 0.000 abstract 1
- 102100037694 Kinesin-like protein KIF20A Human genes 0.000 abstract 1
- 102100023890 Kinetochore protein NDC80 homolog Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100040437 Protein ECT2 Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464422—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464434—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464462—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει πεπτίδια που έχουν αλληλουχία αμινοξέος όπως εκτίθεται στη SEQ ID NO: SEQ ID NO: 19, 22, 30, 34, 344,358, 41, 44, 46, 48, 78, 376,379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117,121, 395,133,135,137, 426, 174,178,186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 ή 288, καθώς επίσης πεπτίδια που έχουν τις ανωτέρω αναφερθείσες αλληλουχίες αμινοξέος, όπου 1,.2 ή μερικά (π.χ., μέχρι 5) αμινοξέα έχουν υποκατασταθεί, απαλειφθεί ή προστεθεί, υπό την προϋπόθεση ότι τα πεπτίδια έχουν κυτταροτοξική διεγερσιμότητα Τ κυττάρου. Η παρούσα εφεύρεση επίσης παρέχει φάρμακα για θεραπεία ή αποτροπή ασθένειας που συνδυάζεται με υπερ-έκφραση των CDH3, ΕΡΗΑ4, ECT2, HIG2, INHBB, KIF20A, KNTC2, ΤΤΚ ή/και URLC10, π.χ. καρκίνων, που περιέχουν ως δραστικό συστατικό ένα ή περισσότερα από αυτά τα πεπτίδια. Τα πεπτίδια της παρούσας εφεύρεσης βρίσκουν περαιτέρω χρησιμότητα ως εμβόλια.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90294907P | 2007-02-21 | 2007-02-21 | |
EP12151711.4A EP2465864B1 (en) | 2007-02-21 | 2008-02-21 | EphA4 derived peptide vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115841T1 true CY1115841T1 (el) | 2017-01-25 |
Family
ID=39709837
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100994T CY1114590T1 (el) | 2007-02-21 | 2013-11-08 | Εμβολια πεπτιδιου για καρκινους που εκφραζουν ογκο-συναφη αντιγονα |
CY20141101067T CY1115841T1 (el) | 2007-02-21 | 2014-12-18 | Εμβολια πεπτιδιου παραγομενα απο epha4 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131100994T CY1114590T1 (el) | 2007-02-21 | 2013-11-08 | Εμβολια πεπτιδιου για καρκινους που εκφραζουν ογκο-συναφη αντιγονα |
Country Status (28)
Country | Link |
---|---|
EP (20) | EP2476695A3 (el) |
JP (6) | JP5239103B2 (el) |
KR (8) | KR20150116463A (el) |
CN (4) | CN104292299B (el) |
AR (1) | AR068302A1 (el) |
AU (1) | AU2008218463B2 (el) |
BR (1) | BRPI0808421B1 (el) |
CA (3) | CA2919248A1 (el) |
CO (1) | CO6190536A2 (el) |
CY (2) | CY1114590T1 (el) |
DK (3) | DK2476694T3 (el) |
ES (6) | ES2532708T3 (el) |
HK (7) | HK1172346A1 (el) |
HR (3) | HRP20131044T1 (el) |
IL (10) | IL200478A (el) |
MX (4) | MX337456B (el) |
MY (2) | MY173379A (el) |
NZ (4) | NZ602119A (el) |
PH (1) | PH12014501642B1 (el) |
PL (3) | PL2465864T3 (el) |
PT (2) | PT2465864E (el) |
RU (1) | RU2464275C2 (el) |
SG (3) | SG10201506589WA (el) |
SI (3) | SI2121731T1 (el) |
TW (5) | TWI615403B (el) |
UA (1) | UA100372C2 (el) |
WO (1) | WO2008102557A1 (el) |
ZA (1) | ZA200905881B (el) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1660677A2 (en) | 2003-08-20 | 2006-05-31 | Oncotherapy Science, Inc. | Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc) |
CN104356225B (zh) | 2007-08-20 | 2018-02-13 | 肿瘤疗法科学股份有限公司 | Cdh3 肽以及含有cdh3 肽的药剂 |
RU2011103199A (ru) | 2008-06-30 | 2012-08-10 | Онкотерапи Сайенс, Инк. (Jp) | Антитела против cdh3, меченные радиоизотопной меткой, и их применение |
TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
TWI580431B (zh) * | 2008-08-19 | 2017-05-01 | 腫瘤療法 科學股份有限公司 | Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗 |
MX2011004176A (es) * | 2008-10-22 | 2011-09-21 | Oncotherapy Science Inc | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo. |
TWI500932B (zh) | 2008-12-05 | 2015-09-21 | Oncotherapy Science Inc | Wdrpuh抗原決定位胜肽以及含此胜肽之疫苗 |
BRPI0923402A2 (pt) * | 2008-12-24 | 2015-08-04 | Oncotherapy Science Inc | Peptídeos c10rf59 e vacinas incluindo os mesmos. |
TW201102081A (en) * | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
US8703808B2 (en) | 2009-06-23 | 2014-04-22 | Centre National De La Recherche Scientifique | Use of derivatives of indoles for the treatment of cancer |
DK2519542T3 (en) | 2009-12-28 | 2019-01-14 | Onco Therapy Science Inc | ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF. |
WO2011116026A2 (en) | 2010-03-15 | 2011-09-22 | The Board Of Trustees Of The University Of Illinois | Inhibitors of beta integrin-g protein alpha subunit binding interactions |
TW201627003A (zh) * | 2010-04-02 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Ect2胜肽及含此胜肽之疫苗 |
MX344586B (es) * | 2010-12-02 | 2016-12-20 | Oncotherapy Science Inc | Peptidos tomm34 y vacunas que los incluyen. |
US9452182B2 (en) * | 2011-12-14 | 2016-09-27 | Board Of Regents, The University Of Texas System | Collateral gene inactivation biomarkers and targets for cancer therapy |
SG11201405578TA (en) * | 2012-03-09 | 2014-11-27 | Oncotherapy Science Inc | Pharmaceutical composition containing peptide |
EP2872531A4 (en) * | 2012-07-10 | 2016-04-06 | Oncotherapy Science Inc | LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME |
EP2872530A4 (en) * | 2012-07-10 | 2016-04-06 | Oncotherapy Science Inc | KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME |
WO2014034754A1 (ja) * | 2012-08-31 | 2014-03-06 | 塩野義製薬株式会社 | Psf1由来ペプチド |
MX362912B (es) | 2012-09-11 | 2019-02-22 | Oncotherapy Science Inc | Péptidos ube2t y vacunas que incluyen los mismos. |
WO2014141652A1 (en) * | 2013-03-11 | 2014-09-18 | Oncotherapy Science, Inc. | Smyd3 peptides and vaccines containing the same |
TWI658049B (zh) | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Kntc2胜肽及含此胜肽之疫苗 |
WO2015005479A1 (ja) * | 2013-07-12 | 2015-01-15 | 大日本住友製薬株式会社 | 腫瘍抗原ペプチド |
JP2015227292A (ja) * | 2014-05-30 | 2015-12-17 | 国立大学法人高知大学 | 膵がん細胞浸潤転移抑制ワクチン |
WO2016001810A1 (en) | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
KR20170030649A (ko) * | 2014-08-04 | 2017-03-17 | 온코세라피 사이언스 가부시키가이샤 | Urlc10-유래 펩티드 및 이를 포함하는 백신 |
GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
CN104975082B (zh) * | 2015-06-05 | 2018-11-02 | 复旦大学附属肿瘤医院 | 一组用于评估肺癌预后的基因及其应用 |
WO2018090257A1 (zh) * | 2016-11-16 | 2018-05-24 | 深圳华大基因研究院 | 多肽及其应用 |
SI3573600T1 (sl) | 2017-01-25 | 2022-07-29 | Ose Immunotherapeutics | Postopek za proizvodnjo obstojne emulzije za dostavo peptida |
WO2018183447A1 (en) * | 2017-03-28 | 2018-10-04 | Zhenglun Zhu | Methods of treating neoplastic diseases |
US11969463B2 (en) * | 2017-08-10 | 2024-04-30 | Good T Cells, Inc. | Method for activating T cells for cancer treatment |
US20210038703A1 (en) * | 2018-02-15 | 2021-02-11 | National University Corporation Asahikawa Medical University | Cancer Antigen Peptide |
KR102322832B1 (ko) * | 2019-04-22 | 2021-11-12 | 한국과학기술연구원 | 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
KR102335916B1 (ko) * | 2019-04-22 | 2021-12-08 | 한국과학기술연구원 | 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
NZ217727A (en) * | 1985-10-03 | 1990-05-28 | Genentech Inc | Nucleic acid encoding alpha or b chain of inhibin, its production and compositions containing it |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
CA2084180A1 (en) * | 1991-12-11 | 1993-06-12 | Paul P. Hung | Expression of specific immunogens using viral antigens |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
EP1464706A3 (en) * | 1994-04-15 | 2004-11-03 | Amgen Inc., | HEK5, HEK7, HEK8, HEK11, EPH-like receptor protein tyrosine kinases |
US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
DE69635895D1 (de) | 1995-08-03 | 2006-05-04 | Rijksuniversiteit Te Leiden Le | Antigen presentierende bläschen, die von zellen ableiten |
US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
EP0960204A4 (en) | 1996-07-26 | 2002-01-23 | Sloan Kettering Inst Cancer | METHODS AND REAGENTS FOR GENETIC IMMUNIZATION |
AU6795898A (en) * | 1997-04-04 | 1998-10-30 | Board Of Regents, The University Of Texas System | Proteins and compositions for modulating mitosis |
FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
EP1627886A1 (en) * | 1997-10-07 | 2006-02-22 | Ono Pharmaceutical Co., Ltd. | Polypeptide, cDNA encoding the same, and use of them |
US20070014787A1 (en) * | 1998-07-15 | 2007-01-18 | Human Genome Sciences, Inc. | 71 human secreted proteins |
AU1220001A (en) * | 1999-10-20 | 2001-04-30 | Zymogenetics Inc. | Novel proteins and polynucleotides encoding them |
US6682902B2 (en) * | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
US20030013649A1 (en) * | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
CN1469926A (zh) * | 2000-03-29 | 2004-01-21 | 科里克萨有限公司 | 治疗和诊断肺癌的组合物和方法 |
WO2002008765A2 (en) | 2000-07-26 | 2002-01-31 | Stanford University | Basal cell markers in breast cancer and uses thereof |
US6830885B1 (en) * | 2000-08-18 | 2004-12-14 | Phenogene Therapeutiques Inc. | Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature |
US20090062512A1 (en) * | 2000-10-10 | 2009-03-05 | Hildebrand William H | Comparative ligand mapping from MHC class I positive cells |
US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
CN100400099C (zh) * | 2001-01-04 | 2008-07-09 | 北京迪威华宇生物技术有限公司 | 预防和治疗人前列腺癌的重组蛋白疫苗 |
AU2002311787A1 (en) * | 2001-03-28 | 2002-10-15 | Zycos Inc. | Translational profiling |
EP1463928A2 (en) * | 2001-04-18 | 2004-10-06 | Protein Design Labs | Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
WO2002102235A2 (en) * | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US20030124579A1 (en) * | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
CN1653080A (zh) * | 2002-03-07 | 2005-08-10 | 路德维格癌症研究院 | 淋巴管和血管的内皮细胞基因 |
US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
US20070015271A1 (en) * | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
US20070224201A1 (en) * | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
CA2507924A1 (en) * | 2002-12-10 | 2004-07-01 | Endocube Sas | Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation |
US20040235071A1 (en) * | 2002-12-20 | 2004-11-25 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476, 62113, 64316, 12264, 32362, 58198, 2887, 3205, 8557, 9600, 9693, 44867, 53058, 55556, 57658, 2208, 10252, 10302, 14218, 33877, 10317, 10485, 25964, 14815, 1363, 1397, 14827, 21708, 3801, 64698, 2179 or 13249 |
TWI324608B (en) * | 2003-02-28 | 2010-05-11 | Oncotherapy Science Inc | Genes and polypeptides relating to human colorectal cancers |
WO2005001138A2 (en) * | 2003-06-18 | 2005-01-06 | Arcturus Bioscience, Inc. | Breast cancer survival and recurrence |
WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
EP1660677A2 (en) * | 2003-08-20 | 2006-05-31 | Oncotherapy Science, Inc. | Hypoxia-inducible protein 2 (hig2), a novel therapeutic potential target of renal cell carcinoma (rcc) |
US20070253954A1 (en) * | 2004-02-27 | 2007-11-01 | Oncotherapy Science, Inc. | Epha4 As Therapeutic Target Of Prc And Pdaca |
WO2005097189A1 (ja) * | 2004-04-09 | 2005-10-20 | Genecare Research Institute Co., Ltd. | 染色体安定化に関する遺伝子を標的とする癌細胞特異的アポトーシス誘導剤 |
JP2008509654A (ja) * | 2004-06-01 | 2008-04-03 | イノジェネティックス・ナムローゼ・フェンノートシャップ | C型肝炎ウイルスに対するctlおよび/またはhtl応答を誘導するためのペプチド |
WO2006031221A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
CN100381460C (zh) * | 2004-11-30 | 2008-04-16 | 北京市肿瘤防治研究所 | Her-2模拟抗原表位及含有该表位的肽 |
MX2007010349A (es) * | 2005-02-24 | 2008-04-09 | Cemines Inc | Composiciones y metodos para clasificar muestras biologicas. |
DK2325305T3 (en) * | 2005-02-25 | 2014-03-03 | Oncotherapy Science Inc | Peptide vaccines for cancers that express TTK-, URLC10- or KOC1 polypeptide |
CN100348614C (zh) * | 2005-06-03 | 2007-11-14 | 北京大学 | 一种肝癌-睾丸特异性抗原蛋白质和抗原肽 |
AU2006277295B2 (en) * | 2005-08-09 | 2011-08-11 | Oncotherapy Science, Inc. | Glypican-3 (GPC3)-derived tumor rejection antigenic peptides useful for HLA-A2-positive patients and pharmaceutical comprising the same |
EP1930427B1 (en) * | 2005-08-09 | 2012-04-11 | Kurume University | Squamous cell carcinoma antigen-derived peptide binding to hla-a24 molecule |
US8003770B2 (en) | 2005-09-13 | 2011-08-23 | Mie University | T-cell receptor and nucleic acid encoding the receptor |
WO2007064743A2 (en) * | 2005-11-30 | 2007-06-07 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
JP5290148B2 (ja) * | 2006-04-10 | 2013-09-18 | ジェネンテック, インコーポレイテッド | Disheveled(Dvl)PDZ修飾因子 |
ATE509096T1 (de) * | 2006-06-16 | 2011-05-15 | Onco Therapy Science Inc | Von sparc abgeleitetes krebsabstossungsantigenpeptid und pharmazeutikum, das dieses enthält |
US20090081659A1 (en) * | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
EP1983003A3 (en) * | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
CN104356225B (zh) * | 2007-08-20 | 2018-02-13 | 肿瘤疗法科学股份有限公司 | Cdh3 肽以及含有cdh3 肽的药剂 |
EP2080812A1 (en) * | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
TWI580431B (zh) * | 2008-08-19 | 2017-05-01 | 腫瘤療法 科學股份有限公司 | Hig2與urlc10抗原決定位胜肽以及含此胜肽之疫苗 |
CA2775978A1 (en) * | 2009-09-29 | 2011-04-07 | Protagen Ag | Marker sequences for pancreatic cancer diseases, pancreatic carcinoma and use thereof |
-
2008
- 2008-02-18 TW TW105108412A patent/TWI615403B/zh active
- 2008-02-18 TW TW097105594A patent/TWI438207B/zh not_active IP Right Cessation
- 2008-02-18 TW TW104120673A patent/TWI596109B/zh not_active IP Right Cessation
- 2008-02-18 TW TW103114624A patent/TWI494319B/zh not_active IP Right Cessation
- 2008-02-18 TW TW103107156A patent/TWI610939B/zh active
- 2008-02-21 EP EP12151723A patent/EP2476695A3/en not_active Withdrawn
- 2008-02-21 CN CN201410449753.0A patent/CN104292299B/zh active Active
- 2008-02-21 EP EP12175480.8A patent/EP2567971A3/en not_active Withdrawn
- 2008-02-21 PL PL12151711T patent/PL2465864T3/pl unknown
- 2008-02-21 KR KR1020157026286A patent/KR20150116463A/ko active IP Right Grant
- 2008-02-21 SI SI200831053T patent/SI2121731T1/sl unknown
- 2008-02-21 EP EP12175489.9A patent/EP2594582A3/en not_active Withdrawn
- 2008-02-21 KR KR1020157013656A patent/KR101644871B1/ko active IP Right Grant
- 2008-02-21 EP EP12151719.7A patent/EP2465865B1/en not_active Not-in-force
- 2008-02-21 KR KR1020137004417A patent/KR101511140B1/ko active IP Right Grant
- 2008-02-21 MX MX2013009905A patent/MX337456B/es unknown
- 2008-02-21 ES ES12151714.8T patent/ES2532708T3/es active Active
- 2008-02-21 EP EP12175484.0A patent/EP2594581A3/en not_active Withdrawn
- 2008-02-21 EP EP12151711.4A patent/EP2465864B1/en not_active Not-in-force
- 2008-02-21 KR KR1020147026715A patent/KR101540000B1/ko active IP Right Grant
- 2008-02-21 MX MX2009009022A patent/MX2009009022A/es active IP Right Grant
- 2008-02-21 CA CA2919248A patent/CA2919248A1/en not_active Abandoned
- 2008-02-21 BR BRPI0808421-1A patent/BRPI0808421B1/pt not_active IP Right Cessation
- 2008-02-21 DK DK12151717.1T patent/DK2476694T3/en active
- 2008-02-21 EP EP12175483.2A patent/EP2570430A3/en not_active Withdrawn
- 2008-02-21 EP EP12151722.1A patent/EP2465867B1/en active Active
- 2008-02-21 KR KR1020097019583A patent/KR101511134B1/ko active IP Right Grant
- 2008-02-21 NZ NZ602119A patent/NZ602119A/en not_active IP Right Cessation
- 2008-02-21 EP EP12151705.6A patent/EP2476692B1/en not_active Not-in-force
- 2008-02-21 PL PL08710443T patent/PL2121731T3/pl unknown
- 2008-02-21 ES ES12151705.6T patent/ES2541863T3/es active Active
- 2008-02-21 KR KR1020147026728A patent/KR101543623B1/ko active IP Right Grant
- 2008-02-21 KR KR1020157002221A patent/KR101644877B1/ko active IP Right Grant
- 2008-02-21 EP EP12175482.4A patent/EP2570429A3/en not_active Withdrawn
- 2008-02-21 EP EP12175490.7A patent/EP2574623A3/en not_active Withdrawn
- 2008-02-21 PL PL12151717T patent/PL2476694T3/pl unknown
- 2008-02-21 EP EP12151720A patent/EP2465866A3/en not_active Withdrawn
- 2008-02-21 MX MX2016002567A patent/MX359680B/es unknown
- 2008-02-21 CA CA2992074A patent/CA2992074C/en active Active
- 2008-02-21 CA CA2678755A patent/CA2678755C/en active Active
- 2008-02-21 NZ NZ591704A patent/NZ591704A/xx not_active IP Right Cessation
- 2008-02-21 EP EP12175481.6A patent/EP2570428A3/en not_active Withdrawn
- 2008-02-21 CN CN201310183458.0A patent/CN103351423B/zh active Active
- 2008-02-21 MY MYPI2012004306A patent/MY173379A/en unknown
- 2008-02-21 MY MYPI20093446A patent/MY155029A/en unknown
- 2008-02-21 WO PCT/JP2008/000290 patent/WO2008102557A1/en active Application Filing
- 2008-02-21 AU AU2008218463A patent/AU2008218463B2/en active Active
- 2008-02-21 JP JP2009534784A patent/JP5239103B2/ja active Active
- 2008-02-21 CN CN200880012937.3A patent/CN101663315B/zh active Active
- 2008-02-21 NZ NZ602122A patent/NZ602122A/en not_active IP Right Cessation
- 2008-02-21 MX MX2013009906A patent/MX337417B/es unknown
- 2008-02-21 EP EP12151714.8A patent/EP2476693B1/en active Active
- 2008-02-21 SG SG10201506589WA patent/SG10201506589WA/en unknown
- 2008-02-21 KR KR1020167010159A patent/KR20160045939A/ko not_active Application Discontinuation
- 2008-02-21 SG SG2012012126A patent/SG179402A1/en unknown
- 2008-02-21 ES ES08710443T patent/ES2435194T3/es active Active
- 2008-02-21 DK DK12151711.4T patent/DK2465864T3/en active
- 2008-02-21 EP EP08710443.6A patent/EP2121731B1/en active Active
- 2008-02-21 CN CN201210352621.7A patent/CN102863514B/zh active Active
- 2008-02-21 EP EP12175479.0A patent/EP2573109A3/en not_active Withdrawn
- 2008-02-21 DK DK08710443.6T patent/DK2121731T3/da active
- 2008-02-21 ES ES12151711.4T patent/ES2527397T3/es active Active
- 2008-02-21 ES ES12151717T patent/ES2530777T3/es active Active
- 2008-02-21 PT PT121517114T patent/PT2465864E/pt unknown
- 2008-02-21 EP EP12151717.1A patent/EP2476694B1/en active Active
- 2008-02-21 EP EP12175487.3A patent/EP2573110A3/en not_active Withdrawn
- 2008-02-21 AR ARP080100718A patent/AR068302A1/es unknown
- 2008-02-21 SI SI200831332T patent/SI2465864T1/sl unknown
- 2008-02-21 NZ NZ579768A patent/NZ579768A/en not_active IP Right Cessation
- 2008-02-21 PT PT87104436T patent/PT2121731E/pt unknown
- 2008-02-21 EP EP12175478A patent/EP2565203A1/en not_active Withdrawn
- 2008-02-21 EP EP12175488.1A patent/EP2583976A3/en not_active Withdrawn
- 2008-02-21 UA UAA200909469A patent/UA100372C2/ru unknown
- 2008-02-21 SI SI200831368T patent/SI2476694T1/sl unknown
- 2008-02-21 RU RU2009135020/10A patent/RU2464275C2/ru active
- 2008-02-21 SG SG10201909675Q patent/SG10201909675QA/en unknown
- 2008-02-21 ES ES12151722.1T patent/ES2540893T3/es active Active
-
2009
- 2009-08-18 IL IL200478A patent/IL200478A/en active IP Right Grant
- 2009-08-25 ZA ZA200905881A patent/ZA200905881B/xx unknown
- 2009-09-21 CO CO09102283A patent/CO6190536A2/es not_active Application Discontinuation
-
2010
- 2010-02-02 JP JP2010021234A patent/JP5239104B2/ja active Active
- 2010-03-10 HK HK12112989A patent/HK1172346A1/xx not_active IP Right Cessation
- 2010-03-10 HK HK12112899.3A patent/HK1172043A1/xx not_active IP Right Cessation
- 2010-03-10 HK HK10102517.8A patent/HK1134507A1/xx not_active IP Right Cessation
- 2010-03-10 HK HK12112988.5A patent/HK1172345A1/xx not_active IP Right Cessation
- 2010-03-10 HK HK12112898.4A patent/HK1172042A1/zh not_active IP Right Cessation
- 2010-03-10 HK HK12112897.5A patent/HK1172041A1/xx not_active IP Right Cessation
- 2010-03-10 HK HK12112987.6A patent/HK1172344A1/xx not_active IP Right Cessation
-
2012
- 2012-04-04 IL IL219045A patent/IL219045A0/en unknown
- 2012-04-04 IL IL219042A patent/IL219042A/en not_active IP Right Cessation
- 2012-04-04 IL IL219044A patent/IL219044A/en active IP Right Grant
- 2012-04-04 IL IL219040A patent/IL219040A/en active IP Right Grant
- 2012-04-04 IL IL219041A patent/IL219041A/en not_active IP Right Cessation
- 2012-04-04 IL IL219046A patent/IL219046A/en not_active IP Right Cessation
- 2012-04-04 IL IL219043A patent/IL219043A/en not_active IP Right Cessation
- 2012-04-04 IL IL219047A patent/IL219047A0/en unknown
- 2012-04-04 IL IL219048A patent/IL219048A/en not_active IP Right Cessation
- 2012-11-29 JP JP2012260421A patent/JP5608953B2/ja active Active
- 2012-11-29 JP JP2012260412A patent/JP5614761B2/ja active Active
-
2013
- 2013-11-05 HR HRP20131044AT patent/HRP20131044T1/hr unknown
- 2013-11-08 CY CY20131100994T patent/CY1114590T1/el unknown
-
2014
- 2014-07-17 PH PH12014501642A patent/PH12014501642B1/en unknown
- 2014-07-24 JP JP2014150295A patent/JP5874158B2/ja not_active Expired - Fee Related
- 2014-12-17 HR HRP20141233AT patent/HRP20141233T1/hr unknown
- 2014-12-18 CY CY20141101067T patent/CY1115841T1/el unknown
-
2015
- 2015-01-28 HR HRP20150108TT patent/HRP20150108T1/hr unknown
- 2015-12-25 JP JP2015252737A patent/JP2016094459A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115841T1 (el) | Εμβολια πεπτιδιου παραγομενα απο epha4 | |
CY1109463T1 (el) | Πεπτιδια kdr και εμβολια που τα περιλαμβανουν | |
CY1118821T1 (el) | Γελες με βαση υαλουρονικο οξυ οι οποιες περιλαμβανουν αναισθητικους παραγοντες | |
CY1118731T1 (el) | Φαρμακευτικες συνθεσεις αλβιγλουτιδης | |
AR076349A1 (es) | Peptido auxiliar del antigeno del cancer | |
BR112012013139A2 (pt) | oligopeptídeos imp-3 e vacinas incluindo os mesmos | |
UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
CY1112867T1 (el) | Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια | |
CO6362049A2 (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo | |
AR113982A1 (es) | Péptido antagonista de la actividad de la interleucina-15 | |
TH120970A (th) | เปปไทด์วัคซีนสำหรับแอนติเจนที่เกี่ยวข้องกับเนื้องอกที่เป็นมะเร็ง | |
TH120970B (th) | เปปไทด์วัคซีนสำหรับแอนติเจนที่เกี่ยวข้องกับเนื้องอกที่เป็นมะเร็ง | |
ES2529713T3 (es) | Péptidos anticonceptivos derivados de veneno de araña | |
CY1114720T1 (el) | Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια |